MX9302957A - Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MX9302957A
MX9302957A MX9302957A MX9302957A MX9302957A MX 9302957 A MX9302957 A MX 9302957A MX 9302957 A MX9302957 A MX 9302957A MX 9302957 A MX9302957 A MX 9302957A MX 9302957 A MX9302957 A MX 9302957A
Authority
MX
Mexico
Prior art keywords
preparation
compound
xantina
compounds
procedure
Prior art date
Application number
MX9302957A
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9302957A publication Critical patent/MX9302957A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un compuesto de fórmula (I): o si es apropiado una sal farmacéuticamente aceptable del mismo, en donde R1 y R2 representan cada uno independientemente una porción de fórmula (a): en donde m representa cero o un número entero 1, 2 ó 3, y A representa un radical hidrocarburo cíclico, substituido o no substituido; R3 representa hidrógeno, alquilo substituido o no substituido, o un grupo aralquilo substituido o no substituido en la porción arilo; y R4 representa hidrógeno, alquilo o alquilcarbonilo; un proceso para la preparación de tal compuesto, una composición farmacéutica que contiene tal compuesto y el uso de tal compuesto en medicina.
MX9302957A 1992-05-21 1993-05-20 Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. MX9302957A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Publications (1)

Publication Number Publication Date
MX9302957A true MX9302957A (es) 1994-05-31

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302957A MX9302957A (es) 1992-05-21 1993-05-20 Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (10)

Country Link
EP (1) EP0641344A1 (es)
JP (1) JPH07506591A (es)
CN (1) CN1094046A (es)
AU (1) AU4081493A (es)
CA (1) CA2136196A1 (es)
GB (1) GB9210839D0 (es)
MX (1) MX9302957A (es)
TW (1) TW277062B (es)
WO (1) WO1993023401A1 (es)
ZA (1) ZA933494B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) * 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2000068231A1 (en) 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
CA2383351C (en) * 1999-08-31 2005-11-01 Vanderbilt University Xanthine derivatives as selective antagonists of a2b adenosine receptors
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
ES2284056T3 (es) * 2003-07-31 2007-11-01 Schering Corporation Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
US7655636B2 (en) 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779374D1 (en) * 1986-08-28 1992-07-02 Sandoz Ag Xanthinderivate.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
DE69132291T2 (de) * 1990-12-21 2000-12-14 Beecham Group P.L.C., Brentford Xanthinderivate

Also Published As

Publication number Publication date
ZA933494B (en) 1994-03-01
GB9210839D0 (en) 1992-07-08
WO1993023401A1 (en) 1993-11-25
EP0641344A1 (en) 1995-03-08
CA2136196A1 (en) 1993-11-25
AU4081493A (en) 1993-12-13
JPH07506591A (ja) 1995-07-20
CN1094046A (zh) 1994-10-26
TW277062B (es) 1996-06-01

Similar Documents

Publication Publication Date Title
MX9302957A (es) Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE69328192D1 (de) Injizierbare Arzneizubereitungen enthaltend Taxanderivate
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
MX9203239A (es) Derivados de 1-(dihidroxifenil)-2-amino-etanol y composiciones farmaceuticas que los contienen.
PT97888A (pt) Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
ES2114931T3 (es) Nuevos esteres esteroidales.
MY103233A (en) Novel thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
ES2035824T3 (es) Procedimiento para preparar compuestos profarmacos y preparaciones que los contienen.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
ATE121739T1 (de) Discodermolideverbindungen, diese enthaltende zubereitungen, verfahren zu ihrer herstellung und deren verwendung.
ATE111912T1 (de) Xanthinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
DE3870167D1 (de) N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
SE8403268D0 (sv) 1,4-dihydropyridin-derivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen
ES2053755T3 (es) Un procedimiento para preparar compuestos heterociclicos.
ES2060592T3 (es) Un tioester y su uso en la preparacion de composiciones farmaceuticas para el tratamiento de los sindromes de isquemia y reperfusion.
HU9203400D0 (en) Method for producing new n-substituted n-nitroso-amino-aceto-nitryl derivatives and pharmaceutical derivatives containing them
SE8603589L (sv) Metylendioxifenantren- och stilbenderivat
SE9203824L (sv) Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ATE90086T1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
EP0402469A4 (en) Catechol compounds, process for their preparation and pharmaceutical preparation containing same
ES2053544T3 (es) Un procedimiento para la preparacion de nuevos derivados de indol tetraciclicos.
FI860098A0 (fi) Nya piperazinderivat, foerfarande foer deras framstaellning och farmaceutiska kompositioner som innehaoller dessa foereningar som aktiv ingrediens.
ATE145647T1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
DE69011235D1 (de) Derivate von N-(Vincristinyl-23) und N-(Noranhydro-5-vinblastinyl-23) von Amino-1-methylphosphonsäure, ihre Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.